Call us toll free: +39 075 80.12.764
Top notch Multipurpose WordPress Theme!

LA TECNOLOGIA BREVETTATA REVIFAST E’ STATO MENZIONATO NELLA PUBBLICAZIONE “HUMAN SIRTUIN REGULATORS: THE SUCCESS STORIES SU FRONTIERS OF PHYSIOLOGY”, RICONOSCIUTO COME UNA STORIA DI SUCCESSO

Lug
08

LA TECNOLOGIA BREVETTATA REVIFAST E’ STATO MENZIONATO NELLA PUBBLICAZIONE “HUMAN SIRTUIN REGULATORS: THE SUCCESS STORIES SU FRONTIERS OF PHYSIOLOGY”, RICONOSCIUTO COME UNA STORIA DI SUCCESSO

The human sirtuins are a group of NAD+-dependent protein deacylases. They “erase”acyl modifications from lysine residues in various cellular targets including histones, transcription factors, and metabolic enzymes. Through these far-reaching activities, sirtuins regulate a diverse array of biological processes ranging from gene transcription to energy metabolism. Human sirtuins have been intensely pursued by both academia and industry as therapeutic targets for a broad spectrum of diseases such as cancer, neurodegenerative diseases, and metabolic disorders. The last two decades have witnessed a flood of small molecule sirtuin regulators. However, there remain relatively few compounds targeting human sirtuins in clinical development. This reflects the
inherent issues concerning the development of isoform-selective and potent molecules with good drug-like properties. In this article, small molecule sirtuin regulators that have advanced into clinical trials will be discussed in details as “successful” examples for future drug development. Special attention is given to the discovery of these compounds, the mechanism of action, pharmacokinetics analysis, formulation, as well as the clinical outcomes observed in the trials.

About the Author:

Lascia un commento!

Devi essere autenticato per postare un commento.